Guest Column | March 4, 2026

FDA’s Draft Guidance On Bayesian Methods: Strategic Implications For Small Biotechs

By Jessica Cordes, senior consultant, Clinical Excellence GmbH

The FDA recently issued its long-awaited “Draft Guidance on the Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products” (January 2026), opening new opportunities for innovative and efficient clinical trial designs. This marks a clear signal to sponsors, especially to smaller companies with limited internal resources, that Bayesian approaches are not only scientifically valid but can also play a role in regulatory decision-making if applied with sufficient rigor.

For small biotechs preparing for first-in-human clinical trials or navigating complex development programs with constrained timelines and budgets, this draft guidance provides both a challenge and an opportunity.

Please read the full Clinical Leader Article.